| Assessment Status | NCPE assessment complete |
| HTA ID | 22007 |
| Drug | Sacituzumab govitecan |
| Brand | Trodelvy® |
| Indication | Is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. |
| Assessment Process | |
| Rapid review commissioned | 07/02/2022 |
| Rapid review completed | 08/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sacituzumab govitecan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 25/04/2022 |
| Full submission received from Applicant | 10/08/2022 |
| Preliminary review sent to Applicant | 22/12/2022 |
| NCPE assessment re-commenced | 01/02/2023 |
| Follow-up to preliminary review sent to Applicant | 13/02/2023 |
| NCPE assessment re-commenced | 16/02/2023 |
| Factual accuracy sent to applicant | 09/03/2023 |
| NCPE assessment re-commenced | 20/03/2023 |
| NCPE assessment completed | 24/03/2023 |
| NCPE assessment outcome | The NCPE recommends that sacituzumab govitecan be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
